Last updated 2026-06-18
- Acquired by Purple Biotech for $100M, Feb 2023
- Raised funding round, Feb 2020
- Raised funding round, Apr 2019
Total raised
—
Last: 2020-02
Stage
Acquired
Founded
2017
Headcount
2
HQ
Yavne
Sector
Health Tech & Life Sciences
About
Immunorizon is developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company extends its pipeline and uses tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells.
Funding history · 3 rounds · — total
2020-02
Undisclosed
2019-04
Undisclosed
2017-12
Undisclosed
Q&A
- What is Immunorizon's primary focus?
- Immunorizon is developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy.
- When was Immunorizon founded?
- Immunorizon was founded in December 2017.
- What is the current status of Immunorizon?
- Immunorizon was acquired by Purple Biotech in February 2023.
- What was the acquisition amount for Immunorizon?
- Immunorizon was acquired for $100,000,000 by Purple Biotech in February 2023.
- How many employees does Immunorizon have?
- Immunorizon has 1-10 employees.
- Who are some of the investors in Immunorizon?
- Immunorizon has received funding from M Ventures and ExploreBio.
- What sector does Immunorizon operate in?
- Immunorizon operates in the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
- Who is the CEO of Immunorizon?
- Oren Bogin is the CEO of Immunorizon.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Business model
B2B
Tags
cancer-therapyimmunologyoncologyantibodiesbiotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Former names | ExploreBio1 |
|---|---|
| Founded | 2017-12 |
| Employees (exact) | 2 |
| Status reason | Acquired by Purple Biotech on Feb, 2023 |
Acquisitions & public offerings
Acquired by Purple Biotech 2023-02 $100.0M
Radar intelligence
Patents
| EPO | 5 |
|---|